12:00 AM
 | 
Oct 21, 2013
 |  BioCentury  |  Strategy

MedImmune's warheads

How MedImmune acquisition of Spirogen provides complete tool set for ADCs

AstraZeneca plc's latest pair of deals - the acquisition of Spirogen Ltd. and a partnership with ADC Therapeutics S.a.r.l. - gives the pharma's MedImmune LLC biologics unit all the tools it needs for antibody-drug conjugates.

ADCs are one of MedImmune's two primary focus areas in cancer. The other area, immunotherapy, was the driver of MedImmune's acquisition of Amplimmune Inc. for $225 million up front and up to $275 million in milestones.

That deal closed Oct. 7, giving MedImmune a pipeline of cancer immunomodulators, including AMP-514, a mAb against PD-1 receptor (PDCD1; PD-1; CD279) that is in preclinical development for cancer (see BioCentury, Sept. 9).

Eight days later MedImmune announced the two ADC deals.

MedImmune will acquire partner Spirogen for $200 million in cash up front plus up to $240 million in milestones.

The AZ unit also partnered with ADC Therapeutics to co-develop two undisclosed preclinical ADC programs. MedImmune will make a $20 million investment in ADC, which also will receive an undisclosed upfront payment and is eligible for milestones.

ADC Therapeutics has a license to Spirogen's ADC technology under a 2012 deal.

MedImmune is not new to the ADC space, though it has not...

Read the full 993 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >